NewcelX Strengthens Its Scientific Leadership
ZURICH – NewcelX Ltd. (NASDAQ: NCEL), a biotechnology company focused on developing transformative therapies for neurodegenerative and metabolic diseases, has made a significant addition to its Scientific Advisory Board. The company is pleased to announce that Professor Tamir Ben-Hur, MD, PhD, a prominent neurologist with extensive experience in neuroimmunology and regenerative medicine, will now contribute his expertise to NewcelX.
Professor Tamir Ben-Hur Joins the Scientific Advisory Board
Professor Ben-Hur, who holds a professorship in Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is celebrated as a leading authority in his field. His impressive track record in stem-cell research and neuroimmunology perfectly aligns with NewcelX's mission to develop groundbreaking therapies.
Significance of His Appointment
In a statement, Prof. Ben-Hur expressed his enthusiasm, stating, "It is an honor to join NewcelX in advancing regenerative and neuroscience-based therapies. The combination of cell therapy and central nervous system drug innovation gives me hope for meaningful therapeutic advances for patients worldwide." His insights are expected to be invaluable as NewcelX continues to break new ground in biotechnology.
Leadership Vision for Treatment Innovations
Chief Scientific Officer of NewcelX, Prof. Michel Revel, emphasized the importance of this appointment. He remarked, "Prof. Ben-Hur's involvement demonstrates a profound clinical expertise and a shared dedication to pioneering innovative cell therapies that tackle the core issues of neurodegenerative diseases." Such leadership ensures that the company will stay at the forefront of scientific discovery.
Commitment to Breakthrough Therapies
Ronen Twito, the Executive Chairman and Chief Executive Officer of NewcelX, voiced the company's pride in welcoming Prof. Ben-Hur. He stated, "His decision signifies strong confidence in our science and our vision to create a leading biotech enterprise focused on developing pioneering therapies for conditions such as ALS and diabetes." This endorsement marks a pivotal moment for NewcelX as it aims to revolutionize treatment options.
NewcelX's Integration of Expertise
The inclusion of Prof. Ben-Hur on the Scientific Advisory Board underscores the solid foundation upon which NewcelX is built. With the merger of Kadimastem Ltd.'s advanced stem-cell methodologies and NLS Pharmaceutics Ltd.'s prowess in central nervous system therapeutics, the company is well-positioned for future innovations.
About NewcelX Ltd.
NewcelX Ltd. specializes in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic disorders. The company leverages an integrated platform that combines state-of-the-art stem-cell technologies with comprehensive neuroscience expertise, facilitating scalable, regenerative treatments. NewcelX is headquartered in Zurich, Switzerland, with significant research and development activities in Ness Ziona, Israel.
Future Perspectives in Biotechnology
As NewcelX continues to expand its capabilities, the collaboration with renowned experts like Prof. Ben-Hur positions the company to pioneer innovative solutions that have the potential to change lives. With a focus on diseases like ALS and Type 1 Diabetes, NewcelX is committed to enhancing treatment options for patients globally.
Frequently Asked Questions
Who is Professor Tamir Ben-Hur?
Professor Tamir Ben-Hur is a distinguished neurologist known for his work in neuroimmunology and regenerative medicine, having joined NewcelX's Scientific Advisory Board.
What is the role of the Scientific Advisory Board at NewcelX?
The Scientific Advisory Board at NewcelX provides guidance and expertise in advancing research and development for innovative therapies in neurodegenerative diseases.
What does NewcelX specialize in?
NewcelX focuses on developing transformative therapies for neurodegenerative and metabolic diseases, integrating advanced stem-cell technologies and neuroscience.
Where is NewcelX headquartered?
NewcelX is headquartered in Zurich, Switzerland, with additional research and development operations in Ness Ziona, Israel.
What are the key areas of research for NewcelX?
NewcelX is dedicated to researching treatments for conditions such as ALS and Type 1 Diabetes, aiming to provide groundbreaking solutions for these challenging diseases.
